Thursday, April 24, 2025

Genentech and C3 AI Improve the Complex Biologics Manufacturing Process with AI

Related stories

BlackCloak Unveils First ID Tool to Fight Deepfake Threats

BlackCloak has launched an industry-first Identity Verification solution to...

BigID Launches AI Privacy Console for Leaders and Risk Intel

BigID, the leading platform for data security, privacy, compliance,...

HiddenLayer Launches AISec 2.0 for Enterprise AI Security

Launch coincides with RSAC 2025 and introduces Model Genealogy, AIBOM,...

Pentera 7 Adds Scalable Testing, AI Reporting for Enterprise

Distributed Attack Orchestration supports parallel security testing in organizations with...

Healthee Raises $50M to Transform Health Benefits

Healthee, the AI-powered platform transforming the health benefits experience,...
spot_imgspot_img

C3 AI, the Enterprise AI application software company, announced that Genentech, the medical biotechnology company, has selected C3 AI Reliability as the continued provider for AI-based predictive maintenance software on the company’s biologics manufacturing equipment.

The biotechnology company began using the AI application in 2021 to ensure centrifuges in the facility remained operational, with patients ultimately benefiting by receiving their medicines on time. Genentech uses this facility to manufacture biologics, a specific class of medicine that is extremely complex, time consuming, and resource intensive to develop and deliver to patients. These medicines help patients with some of the most difficult to treat diseases, from multiple sclerosis and macular degeneration to blood cancers such as lymphoma and leukemia.

Also Read: AION Labs Launches New Startup Leveraging Machine Learning for Molecular Glue Discovery

“We’re proud to partner with Genentech, a company well-known for delivering breakthrough medical innovations for patients, and support its efforts with a robust AI program that allows what is an involved manufacturing process to operate efficiently and ensure patients get the care they need on time,” said C3 AI CEO Thomas M. Siebel.

In 2022, Genentech expanded its use of C3 AI Reliability to new assets beyond centrifuges — scaling its AI footprint to around 200 pieces of equipment total. In addition to increasing the number of assets, the company also broadened employee training for the C3 AI Platform, on which the predictive maintenance application runs. The biotechnology company now has nearly 200 users — from data scientists to facility managers — who are trained on the C3 AI Platform and regularly use the AI application to evaluate equipment health and maintain manufacturing operations.

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img